We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Abbott Diagnostics

Abbott Diagnostics provides medical diagnostic instruments, tests, automation and informatics solutions, including cl... read more Featured Products: More products

Download Mobile App




Multiplex Nested Polymerase Chain Reaction Developed for Congenital Infections

By LabMedica International staff writers
Posted on 13 Jan 2020
Print article
Image: The ABI PRISM 3500 Genetic Analyzer Platform (Photo courtesy of Applied Biosystems)
Image: The ABI PRISM 3500 Genetic Analyzer Platform (Photo courtesy of Applied Biosystems)
Infections are the leading cause of perinatal mortality in low- and middle-income countries, which have a higher prevalence of infections, and are responsible for 50% of infant deaths in the first year of life. Definitive diagnosis of congenital and perinatal infections is largely dependent upon the results of laboratory tests.

The finding of positive maternal immunoglobulin M (IgM) antibodies raised to a certain pathogen in the prenatal serologic screening raises the suspicion of a congenital infection, but the pathogen may not cross the placenta. On the other hand, a positive polymerase chain reaction (PCR) result on amniotic fluid (AF) samples confirms the diagnosis.

Scientists at the University of São Paulo (São Paulo, Brazil) developed a multiplex nested PCR technique for the simultaneous detection of seven pathogens containing DNA in their genomes in suspected cases of congenital infection. Eligible participants were pregnant women with positive IgM antibodies raised to one of the pathogens in the prenatal serologic screening, associated or not with fetal ultrasound abnormalities or positive fetal serology. Neonates whose mothers did not attend prenatal care were included when they presented with symptomatology and laboratory parameters suggestive of infection. The detection rate of the multiplex nested PCR was compared with maternal, fetal, and neonatal serology, as well as placental immunohistochemistry and noncommercial amplifications.

Laboratory examinations included blood count showing leukocytosis or leukopenia, neutropenia, thrombocytopenia, or increased serum C-reactive protein (CRP ultrasensitive kit, Turbitest AA, Wiener Lab, Rosario, Argentina). Maternal and neonatal serum samples were tested by the AxSYM (Abbott Laboratories, Abbott Park, IL, USA) assay based on microparticle enzyme immunoassay technology to assess Toxoplasma gondii IgM and IgG. Herpes simplex, varicella-zoster virus (VZV), and parvovirus B19 (PV) IgM and IgG antibodies were evaluated by the Liaison chemiluminescent assays (DiaSorin Ltd, Saluggia, Italy). The second-round PCR product was submitted to DNA sequencing on the ABI PRISM 3500 Genetic Analyzer Platform, (Applied Biosystems, Foster City, CA, USA) to confirm that the multiplex nested PCR amplified products actually belonged to the detected pathogens.

The scientists reported that of 161 suspected cases, the multiplex nested PCR detected 60 (37.3%), whereas the tests available in hospital laboratories detected 13 of 60 (21.7%) of the cases detected by the multiplex nested PCR, demonstrating a 4.6 times higher detection rate for the multiplex nested PCR. Positive amplifications were to T. gondii (32 cases), cytomegalovirus (14 cases), parvovirus B19 (five cases), and adenovirus (five cases). In four cases, two pathogens were simultaneously detected. All types of biological matrices were suitable for amplification. Sequencing of multiplex nested PCR products confirmed the molecular findings.

The authors concluded that the multiplex nested PCR significantly increased the number of diagnosed congenital infections. Given the scarcity of DNA recovered from amniotic fluid and some neonatal samples, this multiplex nested PCR allows the simultaneous detection of seven pathogens associated with congenital infections in a reliable, faster, cost-effective, and more sensitive way. The study was published in the January 2020 issue of the journal Archives of Pathology and Laboratory Medicine.

Related Links:
University of São Paulo
Wiener Lab
Abbott Laboratories
DiaSorin Ltd
Thermo Fisher Scientific


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Fixed Speed Tube Rocker
GTR-FS
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.